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Abstract: Hepatocellular cancer (HCC) is a very fatal disease due to limited therapeutic options 
as well as due to its association with underlying chronic liver disease in the majority of cases. 
The immune evasion in HCC signifies a major barrier to the delivery of effective immunotherapy. 
Sorafenib is the only Food and Drug Administration-approved drug available with an overall 
response rate of 2%–3% and overall survival of 2.8 months. Chemotherapy has not been used 
routinely because of the relative refractoriness of advanced HCC. The introduction of immune 
checkpoint inhibitors (cytotoxic T-lymphocyte antigen 4, programmed death 1, and programmed 
death-ligand 1) has opened a new horizon for cancer immunotherapy. Future direction in 
immunotherapy for HCC is to rationally combine it with other treatment modalities, including 
surgery, radiofrequency ablation, and cytotoxic agents, to maximize its therapeutic efficacy.
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Introduction
Hepatocellular cancer (HCC) is a very lethal disease because of its association with 
the underlying chronic liver disease in majority of cases. The treatment options are 
also limited. Surgical resection is the preferred therapy; however, tumor extent and 
underlying liver dysfunction make most patients ineligible for resection, leaving liver 
transplantation as the only other curative alternative. The treatment modalities such as 
radiofrequency ablation (RFA), transarterial chemoembolization, and systemic therapy 
are considered in patients who are not candidates for curative option. However, indica-
tions are limited and may not be applicable in all settings. Sorafenib1 is the only Food 
and Drug Administration (FDA)-approved drug available with an overall response 
rate of 2%–3% and overall survival (OS) of 2.8 months. Chemotherapy has not been 
used routinely because of relative refractoriness to chemotherapy of advanced HCC. 
FDA approval of ipilimumab, a human cytotoxic T-lymphocyte antigen 4 (CTLA-
4)-blocking antibody, in 2011, and nivolumab, a programmed death 1 (PD-1) inhibitor, 
in 2014–2015, for patients with metastatic melanoma has opened a new horizon for 
immunotherapy in cancer. Immunotherapy is now considered a main treatment option 
for many solid and hematologic malignancies. Recently, immunotherapy including 
CTLA-4 and PD-1 inhibitor has shown promising antitumor effects in HCC, a tumor 
that is considered resistant to traditional forms of chemotherapy.
Role of cellular immune evasive mechanisms in HCC
The cancer immunogram has recently been proposed by Blank et al2 to better under-
stand the interactions between cancer and immune system. The framework of this 
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immunogram is built on seven parameters that determine the 
effectiveness of immune system. These parameters include 
1) recognition of tumor foreignness due to mutational load, 
2) the immunological status of the patients, 3) the ability of 
the immune cell to infiltrate into the tumor, 4) the inhibitory 
state of the tumor microenvironment such as absence of 
checkpoints, 5) absence of soluble inhibitors (interleukin 6 
[IL-6], C-reactive protein), 6) absence of inhibitory tumor 
metabolism (lactate dehydrogenase, glucose utilization), and 
7) the tumor sensitivity to immune effectors, such as major 
histocompatibility complex expression and interferon-γ 
(IFN-γ) sensitivity. The significance of these parameters may 
differ greatly among the patients, with some factors being 
more dominant than others. Because of the multifactorial 
nature of cancer–immune interactions, combinations of 
biomarker assays will be valuable to define the current states 
of the cancer immunogram. This information will help guide 
treatment choice both during natural cancer–immune interac-
tion and upon immunotherapy. The intrinsic hepatic micro-
environment has made it a relatively immune-tolerogenic 
organ. Existing data describe multiple immune responses 
that include modifications in the functional ability of immune 
cells, change in cytokine level, and the expression of immune 
receptor or ligand. These immune responses promote HCC 
progression, therefore suggesting that antitumor immunity 
may be restored with targeted therapies.
Liver sinusoidal endothelial cells, hepatic dendritic cells, 
and Kupffer cells, by priming hepatic T-cell in the absence 
of costimulation, serve as tolerogenic antigen-presenting 
cells (APCs). This results in defective cytotoxicity and 
immune tolerance.3,4 This function is very significant as 
liver is persistently exposed to antigens absorbed from the 
gastrointestinal tract.
The inability of the immune system to recognize liver 
cancer cells is also explained by other proposed mechanisms. 
These include increase in regulatory T-cell (Tregs), impair-
ment of CD4+ T-cell functions, upregulation of immune 
checkpoint pathways (CTLA-4, PD-1), suppression of natural 
killer (NK) cells, and recruitment of immunosuppressive 
cells, such as monocyte and neutrophils5–11 (Figure 1).
The immune hemostasis is maintained by CD4+CD25+ 
Tregs. Treg has an ability to suppress antitumor immune 
responses. The preclinical models have shown that the defi-
ciency of Tregs may exacerbate the autoimmunity-related 
issues.12,13 The association of Treg and malignancies has also 
been demonstrated in several studies.14,15 Similar increment of 
Tregs was also observed in the peripheral circulation and the 
tumor tissues of HCC patients.5 Shen et al16 and Kobayashi 
et al17 further investigated their association with disease 
progression and outcome. The poor survival was found to 
be related to the upregulation of Treg that also leads to the 
impairment of cytotoxic CD8+ T-cell.7,18,19
Myeloid-derived suppressor cells (MDSCs) symbolize a 
diverse immunosuppressive cell population that is produced in 
response to various tumor-derived cytokines. MDSC accumu-
lation in peripheral circulation and within tumors is driven by 
Myeloid-derived suppressor
cells (MDSCs)
CD4+CD25+Treg
Tumor-associated
macrophages (TAMs)
Cancer-associated
fibroblasts (CAFs)
Figure 1 Immune cells involved in tumor tolerance in hepatocellular cancer (HCC).
Abbreviation: Treg, regulatory T-cell.
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increased granulocyte macrophage colony-stimulating factor 
(GM-CSF) levels produced by cancer cells.20 These cells are 
in different stages of differentiation that constitute myeloid 
progenitor cells, immature myeloid cells, immature granulo-
cytes, monocytes, macrophages, and dendritic cells.21–23 The 
MDSCs suppress the activity of effector T-cells and impaired 
NK cell cytotoxicity and cytokine production.8,24 Hoechst et al 
investigated the frequency and function of a CD14+HLA-
DR−/low, a new population of MDSC in HCC patients. An 
MDSC-mediated immune regulatory pathway was also iden-
tified in these patients. They proposed that the immunosup-
pressive function of MDSC is exerted through the induction 
of CD4+CD25+Foxp3+ Tregs in cocultured CD4+ T-cells.24
Ilkovitch and Lopez25 suggested that liver MDSCs con-
tribute to immunosuppression by interacting with Kupffer 
cells, resulting in the upregulation of a negative T-cell costim-
ulatory molecule, programmed death-ligand 1 (PD -L1). 
In HCC patients who received RFA, MDSC has been found 
to be correlated with tumor progression and prognosis. The 
recurrence-free survival time was inversely associated with 
post-therapy frequency of MDSC.26
NK cells represent an important cell type whose func-
tion is impaired in HCC patients.8 It has been suggested that 
NK cells are inhibited by MDSC through NKp30 receptor.27 
The induction of systemic immunosuppression by expand-
ing CD14 (+) dendritic cells is another recently identified 
mechanism in HCC, which may contribute to its progres-
sion. These regulatory cells suppress T-cell response by 
CTLA-dependent IL-10 and indoleamine-2, 3-dioxygenase 
production in HCC.28
The role of tumor-associated macrophages (TAMs) in 
tumor microenvironment has also been studied. Recent 
immunological evidence has recognized two distinct states 
of macrophage activation that have exactly opposite roles in 
tumor progression and metastasis. M1 macrophages counter-
act tumorigenesis by enhancing Th1 immunocyte responses 
and activating other tumor-killing mechanisms. On the other 
hand, M2 macrophages are immunoregulators, participate 
in Th2 responses, and enhance tumor growth. TAMs have 
recently been found to play a significant role in HCC progres-
sion and metastasis.29 It has been reported that TAMs decrease 
antitumor immunity by suppressing T-cell function directly 
by the expression of PD-L1 and therefore contributed to the 
growth of HCC. Tumor-activated monocytes also secreted 
cytokines that trigger the proliferation of pro-inflammatory 
IL-17-producing CD8 (+) T-cells. These IL-17(+) cells are 
accumulated in HCC and promote angiogenesis that results 
in disease progression.30,31
The high concentration of TAMs in surgically resected 
HCC also has prognostic value. TAM was found to be a 
predictor of poor outcome in most of the studies.19,32 The 
peritumoral infiltration of neutrophils also has been shown 
to enhance angiogenesis progression.33 There is also an 
increasing evidence that cancer-associated fibroblasts (CAFs) 
also promote tumorigenesis and metastasis by stimulating 
angiogenesis, malignant cell survival, and proliferation. 
CAFs are found in HCC with preexisting chronic hepatitis 
and liver cirrhosis. These CAFs may be derived from the 
activation of static fibroblast because of repeated inflam-
matory stimulation and tissue fibrosis. It is suggested that 
during course of HCC progression, fibroblasts in peritumoral 
tissue progressively convert into CAFs. This progression is 
accelerated by tumor-secreted lysophostatidic acid, which 
stimulates the recruitment of peritumor fibroblasts and their 
differentiation into myofibroblasts.34,35
Immune checkpoint inhibitors
Cancer immunotherapy has been revolutionized by the dis-
covery of two checkpoints, CTLA-4, and the programmed 
cell death protein 1 pathway (PD-1/PD-L1; Figure 2). Immu-
notherapy against these negative immunologic regulators 
has given new paradigm shift to immunotherapy and is now 
considered a major component of cancer therapeutic modali-
ties. CTLA-4 was the first negative checkpoint regulator to be 
clinically targeted. Ipilimumab (an anti-CTLA-4 antibody) 
showed a significant OS in patients with advanced melanoma 
in randomized Phase III trial,36 which led to its approval by 
the US FDA in 2011.
HCC-induced immune tolerance is associated with 
multiple immunosuppressive mechanisms. HCC immune 
tolerance is mediated through decreased costimulatory or 
increased inhibitory checkpoint signaling that leads into 
immunosuppression. Significant reductions in expression of 
costimulatory molecules, such as B7-1 and B7-2, have been 
identified in HCC cells,37 resulting in a decrease of B7/CD28-
mediated activation of effector T-cells. Immune-inhibitory 
receptors and ligands also contribute a crucial role in the 
maintenance of HCC immune tolerance. The CTLA-4,28 
PD-1 and its ligand (PD-L1),38 lymphocyte-activation gene 
3 (LAG-3),39 Tim-3 (T-cell membrane protein 3) and its 
ligand (galectin-9),40 and adenosine A2a receptor (A2aR)41 
are among the several inhibitory checkpoints that have been 
related with defective immune process in HCC.
LAG-3 is a molecule that has an inhibitory effect on 
T-cell responses. Li et al39 demonstrated the correlation 
between LAG-3 expression and HBV-specific CD8+ T-cell 
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Figure 2 Check point inhibition and hepatocellular cancer
Notes: (A) Interaction of CTLA-4 with B7 and binding of PD-1 with PD-L1 inhibit T-cell function resulting in tumor proliferation. (B) Antibody-mediated blockade of CTLA-
4 (tremelimumab) and PD-1 (nivolumab) enhanced T-cell function resulting in tumor death.
Abbreviations: APC, antigen-presenting cell; CTLA, cytotoxic T-cell lymphocyte antigen; HCC, hepatocellular cancer; MHC, major histocompatibility complex; PD-1, 
programmed cell death-1; PD-L1, programmed cell death-ligand l; TCR, T-cell receptor.
malfunction. The upregulation of LAG-3 was found to cause 
severe impairment in tumor-infiltrating CD8+ T-cells of HCC 
patients. Li et al40 suggested the Tim-3/galectin-9 signaling 
pathway as a potential immunotherapeutic target in patients 
with HBV-associated HCC. Their work revealed that this 
pathway mediates T-cell dysfunction, which leads to poor 
prognosis in HCC patients. The glucocorticoid-induced 
tumor necrosis factor receptor (GITR) and the inducible T-cell 
costimulator (ICOS) are regulators (stimulatory checkpoint 
molecules) of the immunosuppressive function of Tregs. 
Pedroza-Gonzalez et al42 showed that GITR and ICOS are 
upregulated in Tregs infiltrating HCC, and, therefore, sug-
gested their role as a novel target for immunotherapeutic 
interventions against tumor progression. In another study,43 
they suggested that a combination of both GITR engagement 
and CTLA-4 blockade can improve the antitumor immunity 
by abrogating tumor-infiltrating Treg-mediated suppression 
in HCC.
HCC-induced immune tolerance along with tolerogenic 
hepatic environment and chronic inflammatory conditions 
justify the use of these immune-targeting agents and check-
point inhibitors alone or in combination with other treatment 
modalities in HCC. They are now regarded as promising 
strategies in clinical development. Table 1 summarizes the 
immune check inhibitors (CTLA-4, PD-1, and PD-L1) that 
have been developed and being tested in clinical trials for 
HCC. The clinical parameters of eligible patients used in 
clinical studies for anti-CTLA-4 or anti-PD-1/PD-L1 treat-
ment are mentioned in Table 2. This review is focused on the 
role of these checkpoints and their antibodies relevant for the 
treatment of patients with HCC.
Role of CTLA-4 in HCC and its 
clinical implication and progress
The immune system plays an important role in identify-
ing and eradicating classical highly immunogenic tumors, 
such as melanoma. The tumor-associated antigens (TAAs) 
expressed on transformed tumor cells activate the immune 
system of the body. However, this alone is not sufficient for 
the initiation of an effective response. The interaction between 
antitumor T-cells and APCs is central to the development of 
effective antitumor T-cell immunity. T-cell activation has a 
complex mechanism that is modulated by stimulatory (cell-
surface molecules CD28) and inhibitory CTLA-4 signals. 
Their collaboration is critical for the coordination of effec-
tive immune system’s response to a tumor.44–46 Moreover, 
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CD28 facilitates and maintains a T-cell response. TAAs 
presented in context with APCs bind with T-cell receptors 
(TCRs). The B7 molecules on the APC surface bind with 
CD28 receptors on the T-cell surface and their costimulatory 
signal leads to the translation of TCR stimulation into T-cell 
activation. This ultimate activation of T-cells induces T-cell 
proliferation, cytokine secretion, and gene expression. These 
T-cell-mediated antitumor immune responses are regulated by 
inhibitory signals of CLTA-4 whose expression is upregulated 
upon TCR stimulation. CTLA-4 prevents the costimulatory 
signal by competing with CD28 for binding to B7 ligands 
(CD80 and CD86) on the surface of APC because of higher 
affinity and avidity.47 This binding inhibits the T-cell activa-
tion and proliferation through a homeostatic mechanism to 
prevent autoimmunity under physiological conditions.48 The 
CTLA-4-deficient mice die from lethal lymphoproliferation 
as demonstrated in preclinical model.49
Unlike melanoma, magnitude of tumor-antigen-specific 
T-cells in HCC patients is very limited.50,51 Flecken et 
al50 demonstrated the immunodominance and functional 
alterations of TAA-specific CD8+ T-cell responses in HCC. 
The IFN-γ-producing CD8+ T-cells specific for TAA were 
detected in the periphery as well as in liver and tumor  tissue. 
Although these cells displayed clear immunodominance 
pattern, no steady hierarchy was observed between differ-
ent TAAs. The efficacy of such responses was functionally 
limited as these TAA-specific CD8+ T-cells were found to 
be impaired in their ability to produce IFN-γ.
Chen et al52 studied the role of CTLA-4 in a subcutaneous 
murine hepatoma model. They demonstrated the enhance-
ment of antitumor immunity by coadministration of CTLA-4 
blockade, intratumoral GM-CSF microspheres, and thermal 
ablation. Promising results of this observation were further 
supported upon tumor rechallenge with this regimen. This 
causes rejection of tumor rechallenge in 90% of treated mice 
while cure of established distant tumor was observed in 50% 
of the treated mice.
Sangro et al53 evaluated the efficacy and safety of anti-
CTLA-4 antibodies (tremelimumab) for the treatment of 
HCC. Eligible patients include HCC patients with liver 
cirrhosis (classified as Child–Pugh grades A and B) and 
hepatitis C who were not the candidates of liver-directed 
local therapy or had failed the standard of care for HCC. The 
partial response was observed in 17.6% of patients (three out 
of 17 assessable patients) per Response Evaluation Criteria 
In Solid Tumors (RECIST) criteria, whereas disease control 
rate was 76.4%. The recorded toxicity profile was tolerable 
in the study. The patients most frequently developed skin 
rash (65%), fatigue (55%), and anorexia (50%). A transient 
elevation of serum transaminase activity was observed 
only during the initial course of tremelimumab and was 
not seen with subsequent cycles. Severe immune-mediated 
adverse events were not recorded and, therefore, none of the 
patients required the initiation of steroid. The study included 
the most relevant group of patients (HCC with hepatitis C 
virus [HCV]-related cirrhosis); however, results may show 
differently in chronic HBV patients as far as safety profile 
is concerned with relatively higher hepatic failure rates 
than HCV because of frequent inflammatory flares in HBV 
Table 1 Clinical trials on antibodies targeting PD-1 or PD-L1 in hepatocellular cancer
Antibodies Class Phase Monotherapy/combination Trial ID Status
Anti-cytotoxic T-lymphocyte antigen 4
Tremelimumab Human IgG2 II Monotherapy NCT01008358 Completed
Tremelimumab Human IgG2 I Chemoembolization and radiofrequency ablation NCT01853618 Recruiting
Anti-PD-1
Nivolumab Human IgG4 I Monotherapy NCT01658878 Recruiting
Nivolumab Human IgG4 III Monotherapy vs sorafenib NCT02576509 Recruiting
Nivolumab Human IgG4 I Galunisertib NCT02423343 Recruiting
Anti-PD-L1
MEDI4736 Humanized IgG I Ramucirumab NCT02572687 Recruiting
MEDI4736 Humanized IgG I/II Monotherapy and with Tremelimumab NCT02519348 Recruiting
Abbreviations: PD-1, programmed death 1; PD-L1, programmed death-ligand 1; Ig, immunoglobulin.
Table 2 Clinical parameters of eligible HCC patients for anti-
cytotoxic T-lymphocyte antigen 4 or anti-programmed death 1/ 
programmed death-ligand 1 treatment
Subjects of 18 years or older (men and women)
Histologically confirmed advanced HCC
They are not eligible for surgical and/or locoregional therapies
They have progressive disease after surgical and/or locoregional 
therapies
Eastern Cooperative Oncology Group performance status of 0–1
Dose escalation phase: Child–Pugh score of 7 points or less. Cohort 5: 
Child–Pugh class B (B7–B8). For all other cohorts Child–Pugh score of 
6 points or less
There is no history of autoimmune disease, any prior or current 
clinically significant ascites, or any history of hepatic encephalopathy
Abbreviation: HCC, hepatocellular cancer.
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patients, which may eventually result in variable tremelim-
umab-induced response.54 Nevertheless, the demonstration 
of acceptable toxicity profile of tremelimumab in this study 
provides the first evidence as one of the potentially new 
therapeutic approaches of CTLA-4-targeted immunotherapy 
in HCC patients.
The role of other alternative immunomodulatory mol-
ecules (Tim-3, PD-1, or LAG-3) has been studied to overcome 
T-cell exhaustion during chronic viral infection.55,56
Role of PD-1/PD-L1 in HCC and its 
clinical implication and progress
The promising results in targeting CTLA-4 in cancers such 
as melanoma have attracted researchers to approach and tar-
get other immunologic checkpoints including PD-1/PD-L1.
PD-1 is an immune-inhibitory receptor that modulates the 
activity of T-cells at different stages of the immune response 
through interaction with its ligands, PD-L1 (B7-H1) and 
PD-L2 (B7-DC).57–59
PD-1/PD-L1 is expressed on T-cells, activated B cells, 
monocytes, Tregs, and NK cells. The PD-1/PD-L1 interaction 
inhibits T-lymphocyte proliferation and functions (cytotoxic-
ity, cytokine release), inhibits apoptosis of the tumor cells, 
induces apoptosis of tumor-specific T-cells and promotes the 
conversion of effector cells into Treg cells.60–62
Unlike CTLA-4 that modulates the immune responses 
of early activation of naive and memory T-cells following 
TCR engagement, PD-1 mostly inhibits effector T-cell activ-
ity in peripheral tissues in response to infection or tumor 
progression.63
Limited data are available with respect to the preclinical 
evaluation in HCC. Zabala et al10 evaluated the antitumor 
effect of IL-12-based gene therapy on HCC occurring sponta-
neously in mice. A plasmid vector expressing IL-12 in a liver-
specific and doxycycline-inducible manner was transferred 
to the liver of L-PK/c-myc mice with HCC. Doxycycline 
administration increased serum IL-12 and IFN-γ and induced 
tumor lymphocytic infiltration resulting in tumor stabilization 
or regression in less than half of all treated mice. The tumor 
resistance in nonresponder mice was found to be correlated 
to increase in Tregs and higher expression of the immune-
inhibitory molecules, such as PD-1 and PD-L1. Willimsky et 
al64 established a transgenic murine model of virus-induced 
HCC by hepatocyte-specific adenovirus-induced activation 
of the oncogenic SV40 large T antigen. They demonstrated 
progressive local immune inhibition with considerably 
greater T-cell infiltration in early-stage HCC compared with 
that in advanced-stage HCC.
PD-1/PD-L1 contributed to local tumor-antigen-specific 
tolerance and was expressed in all CD8+ T-cells and HCC.
The expression of PD-1 by T-cells has prognostic rel-
evance. Persistent expression is highly suggestive of an 
exhausted phenotype resulting from a decrease in effector 
function.65,66 Shi et al38 described circulating and intratumor 
PD-1/PD-L1 expression and analyzed their association 
with disease progression in HBV-infected patients. They 
found out that the frequency of circulating PD-1+/CD8+ 
T-cells increased with disease progression. Moreover, PD-1 
expression was found to be significantly increased in tumor-
infiltrating effector CD8+ T-cells. The higher expression of 
PD-1 was correlated with significantly poorer prognosis. Gao 
et al67 investigated the expression of PD-L1 in human HCC 
to define its prognostic significance after curative surgery. 
Results showed that patients with higher expression of PD-L1 
had a significantly poorer prognosis than patients with lower 
expression. Multivariate analysis revealed tumor expression 
of PD-L1 as an independent predictor for postoperative 
recurrence. In addition, tumor- infiltrating cytotoxic and Tregs 
were also found to be independent prognostic factors for both 
survival and recurrence.
Recently, El-Khoueiry et al68 presented Phase I/II data of 
patients with advanced HCC in American Society of Clini-
cal Oncology (ASCO) 2015 annual meeting. The authors 
demonstrated safety and antitumor activity of nivolumab, 
a fully human IgG4 monoclonal antibody PD-1 inhibitor in 
advanced HCC. Nivolumab was administered intravenously 
every 2 weeks for up to 2 years. The dose range was from 0.1 
to 10 mg/kg. Although there was a relatively small sample 
study size of 42 patients, the results compare favorably with 
the existing treatment options. Eleven patients had HCV 
and 10 patients had HBV infection, while 50% of patients 
were unaffected. Approximately 19% of patients (eight out 
of 42 eligible patients) responded to nivolumab. Among 
the responders, two patients achieved complete response, 
while six patients had partial response. The responses to 
nivolumab have been durable in 75% responding patients 
(six out of eight) and were observed across all dose levels 
and etiologic cohorts. Overall, approximately half of the 
total evaluable patients (20 out of 42) had stable disease with 
the longest-lasting 17 months. In addition, at 12 months, 
62% of patients in the study were still surviving with HCC. 
No maximum-tolerated dose was found. Treatment-related 
adverse events of any grade occurred in 68% patients. Grade 
3/4 adverse events were observed in 19% patients. The 
most common (≥5% patients) grade 3 adverse events were 
increases in aspartate aminotransferase (11%) and alanine 
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 aminotransferase (9%), while treatment-related grade 4 
events consisted of elevated lipase (2%).
Sorafenib, a tyrosine kinase inhibitor, is currently the only 
FDA-approved drug for advanced HCC. In comparison to 
this agent in treating HCC, nivolumab showed promising and 
encouraging OS results even in 70% patients who received 
prior sorafenib therapy. The response rate was 19% with 
nivolumab as compared to 2%–3% with sorafenib. There was 
also 20% OS difference at 12 months (62% in patient with 
nivolumab vs 42% with sorafenib). The patients with HCC, 
including those with HBV and HCV infection, had manage-
able safety profile with nivolumab, and this safety profile was 
similar to other tumor types treated with nivolumab. However, 
these findings of nivolumab in HCC need to be validated in 
a large randomized Phase III trial.
Conclusion
HCC is a lethal cancer with limited therapeutic options. 
The immune evasion in HCC signifies a major barrier to the 
delivery of effective immunotherapy. The introduction of 
checkpoint regulators (CTLA-4, PD-1, and PD-L1) and their 
blockade has opened a new horizon for cancer immunother-
apy. Emerging data in HCC suggest that circumventing these 
immunosuppressive pathways can lead to promising objective 
clinical responses with acceptable toxicity profile. Future 
direction in immunotherapy for HCC is to rationally combine 
it with other treatment modalities, including surgery, RFA, 
and cytotoxic agents, to maximize its therapeutic efficacy.
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